These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 16860027)

  • 1. Review of randomized clinical trials of drug-eluting stents for the prevention of in-stent restenosis.
    Eisenberg MJ; Konnyu KJ
    Am J Cardiol; 2006 Aug; 98(3):375-82. PubMed ID: 16860027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Meta-analysis of randomized trials of drug-eluting stents versus bare metal stents in patients with diabetes mellitus.
    Boyden TF; Nallamothu BK; Moscucci M; Chan PS; Grossman PM; Tsai TT; Chetcuti SJ; Bates ER; Gurm HS
    Am J Cardiol; 2007 May; 99(10):1399-402. PubMed ID: 17493468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents.
    Babapulle MN; Joseph L; Bélisle P; Brophy JM; Eisenberg MJ
    Lancet; 2004 Aug 14-20; 364(9434):583-91. PubMed ID: 15313358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Stent coverage and neointimal proliferation in bare metal stents postdilated with a Paclitaxel-eluting balloon versus everolimus-eluting stents: prospective randomized study using optical coherence tomography at 6-month follow-up.
    Poerner TC; Otto S; Gassdorf J; Nitsche K; Janiak F; Scheller B; Goebel B; Jung C; Figulla HR
    Circ Cardiovasc Interv; 2014 Dec; 7(6):760-7. PubMed ID: 25371536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [When are drug-eluting stents effective? A critical analysis of the presently available data].
    Silber S
    Z Kardiol; 2004 Sep; 93(9):649-63. PubMed ID: 15365732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcome of overlapping heterogenous drug-eluting stents and of overlapping drug-eluting and bare metal stents.
    Burzotta F; Siviglia M; Altamura L; Trani C; Leone AM; Romagnoli E; Mazzari MA; Mongiardo R; Niccoli G; Brancati M; Biondi-Zoccai G; Rebuzzi AG; Schiavoni G; Crea F
    Am J Cardiol; 2007 Feb; 99(3):364-8. PubMed ID: 17261399
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immediate and long-term outcomes of drug-eluting stent implantation for unprotected left main coronary artery disease: comparison with bare-metal stent implantation.
    Gao RL; Xu B; Chen JL; Yang YJ; Qiao SB; Li JJ; Qin XW; Yao M; Liu HB; Wu YJ; Yuan JQ; Chen J
    Am Heart J; 2008 Mar; 155(3):553-61. PubMed ID: 18294496
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized evaluation of two drug-eluting stents with identical metallic platform and biodegradable polymer but different agents (paclitaxel or sirolimus) compared against bare stents: 1-year results of the PAINT trial.
    Lemos PA; Moulin B; Perin MA; Oliveira LA; Arruda JA; Lima VC; Lima AA; Caramori PR; Medeiros CR; Barbosa MR; Brito FS; Ribeiro EE; Martinez EE;
    Catheter Cardiovasc Interv; 2009 Nov; 74(5):665-73. PubMed ID: 19670303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
    Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
    Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
    El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A
    Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent).
    Alfonso F; Pérez-Vizcayno MJ; Cárdenas A; García Del Blanco B; Seidelberger B; Iñiguez A; Gómez-Recio M; Masotti M; Velázquez MT; Sanchís J; García-Touchard A; Zueco J; Bethencourt A; Melgares R; Cequier A; Dominguez A; Mainar V; López-Mínguez JR; Moreu J; Martí V; Moreno R; Jiménez-Quevedo P; Gonzalo N; Fernández C; Macaya C;
    J Am Coll Cardiol; 2014 Apr; 63(14):1378-86. PubMed ID: 24412457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Is sirolimus better than paclitaxel? A review of the comparative data on drug-eluting stents.
    Corbett SJ; Babic R; Cosgrave J; Sangiorgi GM; Colombo A
    Cardiovasc Revasc Med; 2006; 7(3):159-64. PubMed ID: 16945823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optical coherence tomography (OCT) in PCI for in-stent restenosis (ISR): rationale and design of the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) study.
    Adriaenssens T; Dens J; Ughi G; Coosemans M; Onsea K; Dubois C; Sinnaeve P; Vrolix M; Desmet W
    EuroIntervention; 2011 May; 7 Suppl K():K100-5. PubMed ID: 22027717
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug-eluting stents: clinical experiences and perspectives.
    Grube E; Gerckens U; Buellesfeld L
    Minerva Cardioangiol; 2002 Oct; 50(5):469-73. PubMed ID: 12384629
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of a paclitaxel coated balloon in combination with a bare metal stent on restenosis and endothelial function: comparison with a drug eluting stent and a bare metal stent.
    Clever YP; Cremers B; Speck U; Dietz U; Böhm M; Scheller B
    Catheter Cardiovasc Interv; 2014 Aug; 84(2):323-31. PubMed ID: 23996969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of effects of drug-eluting stents versus bare metal stents on plasma C-reactive protein levels.
    Kim JY; Ko YG; Shim CY; Park S; Hwang KC; Choi D; Jang Y; Chung N; Shim WH; Cho SY
    Am J Cardiol; 2005 Nov; 96(10):1384-8. PubMed ID: 16275183
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term clinical outcomes after sirolimus-eluting stent implantation for treatment of restenosis within bare-metal versus drug-eluting stents.
    Whan Lee C; Kim SH; Suh J; Park DW; Lee SH; Kim YH; Hong MK; Kim JJ; Park SW; Park SJ
    Catheter Cardiovasc Interv; 2008 Apr; 71(5):594-8. PubMed ID: 18311841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multicenter, randomized study to test immunosuppressive therapy with oral prednisone for the prevention of restenosis after percutaneous coronary interventions: cortisone plus BMS or DES versus BMS alone to eliminate restenosis (CEREA-DES) - study design and rationale.
    Ribichini F; Tomai F; De Luca G; Boccuzzi G; Presbitero P; Pesarini G; Ferrero V; Ghini AS; Pastori F; De Luca L; Zavalloni D; Soregaroli D; Garbo R; Franchi E; Marino P; Minelli M; Vassanelli C
    J Cardiovasc Med (Hagerstown); 2009 Feb; 10(2):192-9. PubMed ID: 19377384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The paclitaxel-eluting stent in percutaneous coronary intervention: Part II. Comparison with the sirolimus-eluting stent, economics, and unanswered questions.
    Ray GM; Nawarskas JJ; Frishman WH
    Cardiol Rev; 2006; 14(3):143-50. PubMed ID: 16628023
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.